ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,584.54
-0.88%
US Tech 100
19,681.20
-2.17%
Dow Jones
39,753.75
0.08%
Brent Oil
85.315
0.24%
Bitcoin
57,535.56
0.32%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Arcellx Inc (ACLX)

  7. Arcellx Inc (ACLX) News

Arcellx Inc

Arcellx Inc (ACLX)

NASDAQ
59.28
1.93
(3.37%)
Closed July 11 4:00PM
Delayed by 15 minutes
59.28
0.02
(0.03%)
After Hours: 7:59PM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

ACLX News

Official News Only

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
4 hours ago
ACLX (3.37%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
June 14 2024
ACLX (3.37%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
June 12 2024
ACLX (3.37%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
May 24 2024
ACLX (3.37%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
May 24 2024
ACLX (3.37%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
May 09 2024
ACLX (3.37%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
March 07 2024
ACLX (3.37%)

Form 8-K - Current report
Edgar (US Regulatory)
February 28 2024
ACLX (3.37%)

ACLX Discussion

View Posts
Monksdream Monksdream 3 months ago
ACLX over $30
👍️0
Monksdream Monksdream 5 months ago
ACLX new 52 week high
👍️0
Monksdream Monksdream 5 months ago
ACLX new 52 week high
👍️0
Monksdream Monksdream 6 months ago
ACLX new 52 week high
👍️0
bandit007 bandit007 2 years ago
Going beast mode into next week.
👍️0
TheyWantYourShares TheyWantYourShares 2 years ago
Nice correction coming here. New IPO at 16… company is flush with capital/cash. Moves coming and getting in now will pay off big IMHO.


Got in on the drop @average: 13.12 … 2 and 3 days ago.


$ACLX


GLTA!!



-TWYS
👍️0
crudeoil24 crudeoil24 2 years ago
Net loss of $44M > no revenues! ( over 9 month period)

ACLX
👍️0
crudeoil24 crudeoil24 2 years ago
Arcellx Inc. ACLX, has set terms for its initial public offering, in which the Maryland-based biotechnology company, which is developing cancer treatments, looks to raise up to $140.25 million. The company said it is offering 8.25 million shares in the IPO, which is expected to price between $15 and $17 a share. With 33.54 million shares expected to be outstanding after the IPO, the expected pricing could value the company at up to $570.24 million. The stock is expected to list on the Nasdaq under the ticker symbol "ACLX." BofA Securities, SVB Leerink, Barclays and William Blair are the lead underwriters. The company recorded a net loss of $44.30 million on no revenue during the nine months ended Sept. 30, after a loss of $23.00 million on no revenue in the same period a year ago. Arcellx is looking to go public at a time of relative investor disdain for IPOs and biotechs, as the Renaissance IPO ETF IPO, -3.27% has plunged 37.2% over the past three months and the iShares Biotechnology ETF IBB, -1.39% has tumbled 19.8%, while the S&P 500 SPX, +0.31% has slipped 3.8%.
👍️0

Your Recent History

NASDAQ
ACLX
Arcellx
BIT
P224J2
NLBNPIT224J2 20991231 17...
BIT
S28193
Societe Generale Effekten
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved